Extramedullary conus spinal cord lipoma

Summary

Extramedullary conus spinal cord lipoma (MONDO:0968987) is a disease. A subtype of conus spinal cord lipoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	extramedullary conus spinal cord lipoma
Mondo ID	MONDO:0968987
Orphanet	645297
UMLS	C5816726
MedGen	1853155
GARD	0027083
Is cancer (heuristic)	no

Disease family

This is a subtype of conus spinal cord lipoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › congenital nervous system disorder › spina bifida › spina bifida occulta › dysraphic spinal cord lipoma › conus spinal cord lipoma › extramedullary conus spinal cord lipoma

Related subtypes (1): chaotic conus spinal cord lipoma

Subtypes (3): terminal extramedullary conus spinal cord lipoma, transitional extramedullary conus spinal cord lipoma, posterior extramedullary conus spinal cord lipoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.